Adjuvant thalidomide and metronomic chemotherapy for the treatment of canine malignant mammary gland neoplasms
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFMG |
Texto Completo: | http://hdl.handle.net/1843/39983 |
Resumo: | Background/Aim: The aim of the present study was to evaluate a multimodal approach for the treatment of canine malignant mammary gland neoplasms, including surgery, chemotherapy, thalidomide, and metronomic chemotherapy (MC). Materials and Methods: Fifty-eight female dogs were submitted to four different treatments: surgery; surgery with chemotherapy; surgery with chemotherapy and thalidomide; and surgery with chemotherapy and metronomic chemotherapy and overall survival was evaluated. Results: No statistical difference was found in the proliferative index and microvessel density of primary neoplasms and distant metastases following thalidomide treatment. Diffuse intense inflammatory infiltrate was predominant in primary tumors and diffuse moderate inflammatory infiltrate in metastatic lesions. No statistically significant difference was observed in median survival time (MST) between treatment groups when including all clinical stages (p=0.3177). However, animals diagnosed with distant metastasis treated with surgery and chemotherapy associated with thalidomide or MC presented longer MST when compared to animals treated only with surgery or surgery and chemotherapy (p<0.0001). Conclusion: The proposed multimodal therapy protocols including antiangiogenic and immunomodulatory therapies demonstrated a clinical benefit for patients in advanced clinical stages. |
id |
UFMG_3fe21c45bd805d56468c2f930df8ceeb |
---|---|
oai_identifier_str |
oai:repositorio.ufmg.br:1843/39983 |
network_acronym_str |
UFMG |
network_name_str |
Repositório Institucional da UFMG |
repository_id_str |
|
spelling |
2022-03-11T15:19:08Z2022-03-11T15:19:08Z20183261659166610.21873/invivo.1142917917549http://hdl.handle.net/1843/39983Background/Aim: The aim of the present study was to evaluate a multimodal approach for the treatment of canine malignant mammary gland neoplasms, including surgery, chemotherapy, thalidomide, and metronomic chemotherapy (MC). Materials and Methods: Fifty-eight female dogs were submitted to four different treatments: surgery; surgery with chemotherapy; surgery with chemotherapy and thalidomide; and surgery with chemotherapy and metronomic chemotherapy and overall survival was evaluated. Results: No statistical difference was found in the proliferative index and microvessel density of primary neoplasms and distant metastases following thalidomide treatment. Diffuse intense inflammatory infiltrate was predominant in primary tumors and diffuse moderate inflammatory infiltrate in metastatic lesions. No statistically significant difference was observed in median survival time (MST) between treatment groups when including all clinical stages (p=0.3177). However, animals diagnosed with distant metastasis treated with surgery and chemotherapy associated with thalidomide or MC presented longer MST when compared to animals treated only with surgery or surgery and chemotherapy (p<0.0001). Conclusion: The proposed multimodal therapy protocols including antiangiogenic and immunomodulatory therapies demonstrated a clinical benefit for patients in advanced clinical stages.Justificativa/objetivo: O objetivo do presente estudo foi avaliar uma abordagem multimodal para o tratamento de neoplasias malignas da glândula mamária canina, incluindo cirurgia, quimioterapia, talidomida e quimioterapia metronômica (CM). Materiais e Métodos: Cinquenta e oito cadelas foram submetidas a quatro tratamentos diferentes: cirurgia; cirurgia com quimioterapia; cirurgia com quimioterapia e talidomida; e cirurgia com quimioterapia e quimioterapia metronômica e a sobrevida global foi avaliada. Resultados: Não foi encontrada diferença estatística no índice proliferativo e densidade microvascular de neoplasias primárias e metástases à distância após tratamento com talidomida. O infiltrado inflamatório intenso difuso foi predominante nos tumores primários e o infiltrado inflamatório moderado difuso nas lesões metastáticas. Não foi observada diferença estatisticamente significativa no tempo médio de sobrevida (MST) entre os grupos de tratamento ao incluir todos os estágios clínicos (p=0,3177). No entanto, animais com diagnóstico de metástase à distância tratados com cirurgia e quimioterapia associada à talidomida ou MC apresentaram maior tempo de MST quando comparados aos animais tratados apenas com cirurgia ou cirurgia e quimioterapia (p<0,0001). Conclusão: Os protocolos de terapia multimodal propostos, incluindo terapias antiangiogênicas e imunomoduladoras, demonstraram benefício clínico para pacientes em estágios clínicos avançados.engUniversidade Federal de Minas GeraisUFMGBrasilICB - DEPARTAMENTO DE PATOLOGIAIn vivoQuimioterapia metronômicaTalidomidaMetástaseGlândula mamáriaCaninoAdjuvant thalidomide and metronomic chemotherapy for the treatment of canine malignant mammary gland neoplasmsTalidomida adjuvante e quimioterapia metronômica para o tratamento de neoplasias malignas de glândula mamária caninainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365760/Cecilia Bonolode CamposGleidice Eunice LavalleLidianne Narducci MonteiroGabriela Rafaela Arantes PêgasSilvia Ligório FialhoDébora BalabramGeovanni Dantas Cassaliapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/39983/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINAL2018_Adjuvant Thalidomide and Metronomic Chemotherapy for the.pdf2018_Adjuvant Thalidomide and Metronomic Chemotherapy for the.pdfapplication/pdf223868https://repositorio.ufmg.br/bitstream/1843/39983/2/2018_Adjuvant%20Thalidomide%20and%20Metronomic%20Chemotherapy%20for%20the.pdfb06e651b45e0dc1c614f7957d8e7c68eMD521843/399832022-03-11 12:19:08.638oai:repositorio.ufmg.br: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Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2022-03-11T15:19:08Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
dc.title.pt_BR.fl_str_mv |
Adjuvant thalidomide and metronomic chemotherapy for the treatment of canine malignant mammary gland neoplasms |
dc.title.alternative.pt_BR.fl_str_mv |
Talidomida adjuvante e quimioterapia metronômica para o tratamento de neoplasias malignas de glândula mamária canina |
title |
Adjuvant thalidomide and metronomic chemotherapy for the treatment of canine malignant mammary gland neoplasms |
spellingShingle |
Adjuvant thalidomide and metronomic chemotherapy for the treatment of canine malignant mammary gland neoplasms Cecilia Bonolode Campos Quimioterapia metronômica Talidomida Metástase Glândula mamária Canino |
title_short |
Adjuvant thalidomide and metronomic chemotherapy for the treatment of canine malignant mammary gland neoplasms |
title_full |
Adjuvant thalidomide and metronomic chemotherapy for the treatment of canine malignant mammary gland neoplasms |
title_fullStr |
Adjuvant thalidomide and metronomic chemotherapy for the treatment of canine malignant mammary gland neoplasms |
title_full_unstemmed |
Adjuvant thalidomide and metronomic chemotherapy for the treatment of canine malignant mammary gland neoplasms |
title_sort |
Adjuvant thalidomide and metronomic chemotherapy for the treatment of canine malignant mammary gland neoplasms |
author |
Cecilia Bonolode Campos |
author_facet |
Cecilia Bonolode Campos Gleidice Eunice Lavalle Lidianne Narducci Monteiro Gabriela Rafaela Arantes Pêgas Silvia Ligório Fialho Débora Balabram Geovanni Dantas Cassali |
author_role |
author |
author2 |
Gleidice Eunice Lavalle Lidianne Narducci Monteiro Gabriela Rafaela Arantes Pêgas Silvia Ligório Fialho Débora Balabram Geovanni Dantas Cassali |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Cecilia Bonolode Campos Gleidice Eunice Lavalle Lidianne Narducci Monteiro Gabriela Rafaela Arantes Pêgas Silvia Ligório Fialho Débora Balabram Geovanni Dantas Cassali |
dc.subject.other.pt_BR.fl_str_mv |
Quimioterapia metronômica Talidomida Metástase Glândula mamária Canino |
topic |
Quimioterapia metronômica Talidomida Metástase Glândula mamária Canino |
description |
Background/Aim: The aim of the present study was to evaluate a multimodal approach for the treatment of canine malignant mammary gland neoplasms, including surgery, chemotherapy, thalidomide, and metronomic chemotherapy (MC). Materials and Methods: Fifty-eight female dogs were submitted to four different treatments: surgery; surgery with chemotherapy; surgery with chemotherapy and thalidomide; and surgery with chemotherapy and metronomic chemotherapy and overall survival was evaluated. Results: No statistical difference was found in the proliferative index and microvessel density of primary neoplasms and distant metastases following thalidomide treatment. Diffuse intense inflammatory infiltrate was predominant in primary tumors and diffuse moderate inflammatory infiltrate in metastatic lesions. No statistically significant difference was observed in median survival time (MST) between treatment groups when including all clinical stages (p=0.3177). However, animals diagnosed with distant metastasis treated with surgery and chemotherapy associated with thalidomide or MC presented longer MST when compared to animals treated only with surgery or surgery and chemotherapy (p<0.0001). Conclusion: The proposed multimodal therapy protocols including antiangiogenic and immunomodulatory therapies demonstrated a clinical benefit for patients in advanced clinical stages. |
publishDate |
2018 |
dc.date.issued.fl_str_mv |
2018 |
dc.date.accessioned.fl_str_mv |
2022-03-11T15:19:08Z |
dc.date.available.fl_str_mv |
2022-03-11T15:19:08Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1843/39983 |
dc.identifier.doi.pt_BR.fl_str_mv |
10.21873/invivo.11429 |
dc.identifier.issn.pt_BR.fl_str_mv |
17917549 |
identifier_str_mv |
10.21873/invivo.11429 17917549 |
url |
http://hdl.handle.net/1843/39983 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
In vivo |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.publisher.initials.fl_str_mv |
UFMG |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
ICB - DEPARTAMENTO DE PATOLOGIA |
publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
instname_str |
Universidade Federal de Minas Gerais (UFMG) |
instacron_str |
UFMG |
institution |
UFMG |
reponame_str |
Repositório Institucional da UFMG |
collection |
Repositório Institucional da UFMG |
bitstream.url.fl_str_mv |
https://repositorio.ufmg.br/bitstream/1843/39983/1/License.txt https://repositorio.ufmg.br/bitstream/1843/39983/2/2018_Adjuvant%20Thalidomide%20and%20Metronomic%20Chemotherapy%20for%20the.pdf |
bitstream.checksum.fl_str_mv |
fa505098d172de0bc8864fc1287ffe22 b06e651b45e0dc1c614f7957d8e7c68e |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
repository.mail.fl_str_mv |
|
_version_ |
1803589173432549376 |